Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly and Company LLY is one of the two companies that dominate the booming cardiometabolic space, driven by its ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.

Researchers investigate the effects of tirzepatide on food preoccupation by influencing the brain’s mesolimbic circuitry.

A rare intracranial recording shows how a low-frequency brain signal vanished during tirzepatide-associated symptom relief and resurfaced weeks before dysregulated eating returned. Study: Brain ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide both led to improvements in self-reported physical function, but not mental health.

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the ...

A first-in-human study suggested that tirzepatide — a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist — modulated abnormal activity in the brain’s nucleus accumbens, ...

Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.

Weight regain after discontinuation of tirzepatide was accompanied by a reversal of cardiometabolic improvements in a post-hoc analysis. For waist circumference, systolic blood pressure, and HbA1c ...